Acurx Gains FDA Guidance for Ibezapolstat Phase 3 Program
Staten Island, New York, August 3, 2026 Acurx Pharmaceuticals, Inc. announced further regulatory guidance from the U.S. Food and...
Phase 3 Clinical Trial
Advertisement
Otsuka’s SIMTRIYO® Becomes First Approved NDSRI for ADHD
PRINCETON, N.J., July 27, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) have announced...
Fosun Pharma Signs Global Option Deal for AriBio’s AR1001
SHANGHAI and SEONGNAM-SI, South Korea, May 13, 2026 Fosun Pharma and AriBio announced the signing of an exclusive global...
BridgeBio BBP-418 Shows Strong Phase 3 Results in LGMD2I/R9
PALO ALTO, CA — March 11, 2026 BridgeBio Pharma announced that its investigational therapy BBP-418 demonstrated consistent efficacy and...
Celcuity Reports Phase 3 Gedatolisib Results in Breast Cancer
Minneapolis, USA – March 9, 2026 Celcuity Inc. has announced the publication of positive Phase 3 VIKTORIA-1 clinical trial...
Advertisements
Telix ProstACT Phase 3 Study Shows Positive Safety Results
Melbourne, Australia & Indianapolis, United States – March 10, 2026 Telix Pharmaceuticals has announced that Part 1 of the...
Johnson & Johnson Wins FDA Approval for Tecvayli–Darzalex Myeloma Therapy
HORSHAM, Pennsylvania – March 5, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration has approved...
CG Oncology Advances Phase 3 Timeline for NMIBC Trial
IRVINE, California | January 9, 2026 — CG Oncology, Inc., a late-stage clinical biopharmaceutical company, has announced an accelerated...
Ultragenyx Reports Phase 3 Setrusumab Results in OI
NOVATO, Calif., December 29, 2025 — Ultragenyx Pharmaceutical announced results from its Phase 3 Orbit and Cosmic clinical trials...
SELLAS Updates Phase 3 REGAL Trial in AML
NEW YORK, December 29, 2025 — SELLAS Life Sciences Group has provided a key update on its pivotal Phase...
Advertisement
